Tags

Type your tag names separated by a space and hit enter

Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses.
Nat Commun. 2021 08 06; 12(1):4740.NC

Abstract

Unraveling the long-term kinetics of antibodies to SARS-CoV-2 and the individual characteristics influencing it, including the impact of pre-existing antibodies to human coronaviruses causing common cold (HCoVs), is essential to understand protective immunity to COVID-19 and devise effective surveillance strategies. IgM, IgA and IgG levels against six SARS-CoV-2 antigens and the nucleocapsid antigen of the four HCoV (229E, NL63, OC43 and HKU1) were quantified by Luminex, and antibody neutralization capacity was assessed by flow cytometry, in a cohort of health care workers followed up to 7 months (N = 578). Seroprevalence increases over time from 13.5% (month 0) and 15.6% (month 1) to 16.4% (month 6). Levels of antibodies, including those with neutralizing capacity, are stable over time, except IgG to nucleocapsid antigen and IgM levels that wane. After the peak response, anti-spike antibody levels increase from ~150 days post-symptom onset in all individuals (73% for IgG), in the absence of any evidence of re-exposure. IgG and IgA to HCoV are significantly higher in asymptomatic than symptomatic seropositive individuals. Thus, pre-existing cross-reactive HCoVs antibodies could have a protective effect against SARS-CoV-2 infection and COVID-19 disease.

Authors+Show Affiliations

ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. Immunology Unit, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain. Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique.ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain. Spanish Consortium for Research in Epidemiology and Public Health, Madrid, Spain.ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain. School of Health Sciences TecnoCampus Universitat Pompeu Fabra, Mataró, Spain.ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain. Department of Preventive Medicine and Epidemiology, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain.ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.Biomolecular screening and Protein Technologies Unit, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, Badalona, Catalonia, Spain.IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, Badalona, Catalonia, Spain.IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, Badalona, Catalonia, Spain. University of Vic-Central University of Catalonia (UVic-UCC), Vic, Catalonia, Spain.ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain. Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique. Spanish Consortium for Research in Epidemiology and Public Health, Madrid, Spain.Occupational Health Department, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.Occupational Health Department, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain. Spanish Consortium for Research in Epidemiology and Public Health, Madrid, Spain.ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain. Spanish Consortium for Research in Epidemiology and Public Health, Madrid, Spain. Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain.Department of Preventive Medicine and Epidemiology, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain. Julia McFarlane Diabetes Research Centre, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. Department of Microbiology, Immunology and Infectious Diseases, Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.Biomolecular screening and Protein Technologies Unit, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.Occupational Health Department, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. Immunology Unit, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. Immunology Unit, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain. Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique. International Health Department, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain. gemma.moncunill@isglobal.org.ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain. carlota.dobano@isglobal.org. Spanish Consortium for Research in Epidemiology and Public Health, Madrid, Spain. carlota.dobano@isglobal.org.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

34362897

Citation

Ortega, Natalia, et al. "Seven-month Kinetics of SARS-CoV-2 Antibodies and Role of Pre-existing Antibodies to Human Coronaviruses." Nature Communications, vol. 12, no. 1, 2021, p. 4740.
Ortega N, Ribes M, Vidal M, et al. Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses. Nat Commun. 2021;12(1):4740.
Ortega, N., Ribes, M., Vidal, M., Rubio, R., Aguilar, R., Williams, S., Barrios, D., Alonso, S., Hernández-Luis, P., Mitchell, R. A., Jairoce, C., Cruz, A., Jimenez, A., Santano, R., Méndez, S., Lamoglia, M., Rosell, N., Llupià, A., Puyol, L., ... Dobaño, C. (2021). Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses. Nature Communications, 12(1), 4740. https://doi.org/10.1038/s41467-021-24979-9
Ortega N, et al. Seven-month Kinetics of SARS-CoV-2 Antibodies and Role of Pre-existing Antibodies to Human Coronaviruses. Nat Commun. 2021 08 6;12(1):4740. PubMed PMID: 34362897.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses. AU - Ortega,Natalia, AU - Ribes,Marta, AU - Vidal,Marta, AU - Rubio,Rocío, AU - Aguilar,Ruth, AU - Williams,Sarah, AU - Barrios,Diana, AU - Alonso,Selena, AU - Hernández-Luis,Pablo, AU - Mitchell,Robert A, AU - Jairoce,Chenjerai, AU - Cruz,Angeline, AU - Jimenez,Alfons, AU - Santano,Rebeca, AU - Méndez,Susana, AU - Lamoglia,Montserrat, AU - Rosell,Neus, AU - Llupià,Anna, AU - Puyol,Laura, AU - Chi,Jordi, AU - Melero,Natalia Rodrigo, AU - Parras,Daniel, AU - Serra,Pau, AU - Pradenas,Edwards, AU - Trinité,Benjamin, AU - Blanco,Julià, AU - Mayor,Alfredo, AU - Barroso,Sonia, AU - Varela,Pilar, AU - Vilella,Anna, AU - Trilla,Antoni, AU - Santamaria,Pere, AU - Carolis,Carlo, AU - Tortajada,Marta, AU - Izquierdo,Luis, AU - Angulo,Ana, AU - Engel,Pablo, AU - García-Basteiro,Alberto L, AU - Moncunill,Gemma, AU - Dobaño,Carlota, Y1 - 2021/08/06/ PY - 2021/03/03/received PY - 2021/07/16/accepted PY - 2021/8/7/entrez PY - 2021/8/8/pubmed PY - 2021/8/17/medline SP - 4740 EP - 4740 JF - Nature communications JO - Nat Commun VL - 12 IS - 1 N2 - Unraveling the long-term kinetics of antibodies to SARS-CoV-2 and the individual characteristics influencing it, including the impact of pre-existing antibodies to human coronaviruses causing common cold (HCoVs), is essential to understand protective immunity to COVID-19 and devise effective surveillance strategies. IgM, IgA and IgG levels against six SARS-CoV-2 antigens and the nucleocapsid antigen of the four HCoV (229E, NL63, OC43 and HKU1) were quantified by Luminex, and antibody neutralization capacity was assessed by flow cytometry, in a cohort of health care workers followed up to 7 months (N = 578). Seroprevalence increases over time from 13.5% (month 0) and 15.6% (month 1) to 16.4% (month 6). Levels of antibodies, including those with neutralizing capacity, are stable over time, except IgG to nucleocapsid antigen and IgM levels that wane. After the peak response, anti-spike antibody levels increase from ~150 days post-symptom onset in all individuals (73% for IgG), in the absence of any evidence of re-exposure. IgG and IgA to HCoV are significantly higher in asymptomatic than symptomatic seropositive individuals. Thus, pre-existing cross-reactive HCoVs antibodies could have a protective effect against SARS-CoV-2 infection and COVID-19 disease. SN - 2041-1723 UR - https://www.unboundmedicine.com/medline/citation/34362897/Seven_month_kinetics_of_SARS_CoV_2_antibodies_and_role_of_pre_existing_antibodies_to_human_coronaviruses_ L2 - https://doi.org/10.1038/s41467-021-24979-9 DB - PRIME DP - Unbound Medicine ER -